These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 15213291)

  • 21. [Chronic treatment with PDE-5 inhibitors is there anything more than treating erectile dysfunction?].
    Vela Navarrete R; García Cardoso JV; López Farre A; Quesada Romero P; Pardo Montero M
    Actas Urol Esp; 2007 Mar; 31(3):179-84. PubMed ID: 17658146
    [No Abstract]   [Full Text] [Related]  

  • 22. Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat.
    de Tejada IS
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S40-2. PubMed ID: 15224136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Levitra (vardenafil)--a new PDE 5 inhibitor for the treatment of erectile dysfunction].
    Katsarov M
    Akush Ginekol (Sofiia); 2004; 43 Suppl 1():31-2. PubMed ID: 15323315
    [No Abstract]   [Full Text] [Related]  

  • 24. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.
    Mehrotra N; Gupta M; Kovar A; Meibohm B
    Int J Impot Res; 2007; 19(3):253-64. PubMed ID: 16988721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of action of PDE5 inhibition in erectile dysfunction.
    Corbin JD
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S4-7. PubMed ID: 15224127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sildenafil-associated NAION.
    Gandhi JS
    Ophthalmology; 2003 Sep; 110(9):1860-1; author reply 1861. PubMed ID: 13129901
    [No Abstract]   [Full Text] [Related]  

  • 27. Non-arteritic anterior ischemic optic neuropathy, erectile dysfunction drugs, and amiodarone: is there a relationship?
    Fraunfelder FW; Shults T
    J Neuroophthalmol; 2006 Mar; 26(1):1-3. PubMed ID: 16518158
    [No Abstract]   [Full Text] [Related]  

  • 28. Diabetic neuropathy - a further indication for phosphodiesterase type 5 inhibitors?
    Oliver JJ
    Int J Clin Pract; 2006 Sep; 60(9):1026-7. PubMed ID: 16939541
    [No Abstract]   [Full Text] [Related]  

  • 29. Cardiovascular implications in the use of PDE5 inhibitor therapy.
    Maurice DH
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S20-3. PubMed ID: 15224131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction.
    Kang KK; Yu JY; Yoo M; Kwon JW
    Int J Impot Res; 2005; 17(5):409-16. PubMed ID: 15920460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Phosphodiesterase-5 inhibitor with broad temporal effectiveness window].
    MMW Fortschr Med; 2004 Apr; 146(16):62. PubMed ID: 15222506
    [No Abstract]   [Full Text] [Related]  

  • 32. Visual loss associated with erectile dysfunction drugs.
    Dündar SO
    Can J Ophthalmol; 2007 Feb; 42(1):10-2. PubMed ID: 17361234
    [No Abstract]   [Full Text] [Related]  

  • 33. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
    Hotston M; Shukla N; Bloor J; Persad R; Jeremy JY
    BJU Int; 2006 Dec; 98(6):1331-2. PubMed ID: 17125493
    [No Abstract]   [Full Text] [Related]  

  • 34. Evaluation and diagnostic testing of erectile dysfunction in the era of phosphodiesterase type 5 inhibitors.
    Jacobsohn K; Wang R
    Asian J Androl; 2007 Jan; 9(1):3-7. PubMed ID: 17187154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors.
    Bella AJ; Brant WO; Lue TF; Brock GB
    Can J Urol; 2006 Oct; 13(5):3233-8. PubMed ID: 17076943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ophthalmic aspects of erectile dysfunction drugs.
    Verit A; Oguz H
    Am J Ophthalmol; 2006 Mar; 141(3):598; author reply 599. PubMed ID: 16490529
    [No Abstract]   [Full Text] [Related]  

  • 37. Commentary on apomorphine versus sildenafil for erectile dysfunction.
    Carson CC
    J Urol; 2008 May; 179(5 Suppl):S95-6. PubMed ID: 18405768
    [No Abstract]   [Full Text] [Related]  

  • 38. Potent and selective xanthine-based inhibitors of phosphodiesterase 5.
    Arnold NJ; Arnold R; Beer D; Bhalay G; Collingwood SP; Craig S; Devereux N; Dodds M; Dunstan AR; Fairhurst RA; Farr D; Fullerton JD; Glen A; Gomez S; Haberthuer S; Hatto JD; Howes C; Jones D; Keller TH; Leuenberger B; Moser HE; Muller I; Naef R; Nicklin PA; Sandham DA; Turner KL; Tweed MF; Watson SJ; Zurini M
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2376-9. PubMed ID: 17337182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association?
    Schiefer J; Sparing R
    Int J Impot Res; 2005; 17(4):383-4. PubMed ID: 15674402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclic GMP phosphodiesterase-5: target of sildenafil.
    Corbin JD; Francis SH
    J Biol Chem; 1999 May; 274(20):13729-32. PubMed ID: 10318772
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.